Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Laparoscopic radical hysterectomy (LRH) and open abdominal radical hysterectomy (ARH) have been used for cervical cancer treatment. We aimed to perform a meta-analysis to compare the efficacy and safety of LRH and ARH in the treatment of cervical cancer to provide reliable evidence to the clinical cervical cancer treatment.
Methods: Two investigators independently searched PubMed and other databases for randomized controlled trials (RCTs) comparing LRH and ARH for cervical cancer treatment up to May 31, 2022. The risk of bias assessment tool recommended by Cochrane library was used for quality assessment. RevMan 5.3 software was used for meta-analysis.
Results: Fourteen RCTs with a total of 1700 patients with cervical cancer were finally included. Meta-analyses indicated that compared with ARH, LRH reduced the intraoperative blood loss (mean difference [MD]=-58.08; 95% CI, -70.91, -45.24), the time to first passage of flatus (MD=-14.50; 95% CI, -16.55, -12.44) (all P <0.05), and increase the number of lymph nodes removed (MD=3.47; 95% CI, 0.51, 6.43; P =0.02). There were no significant differences in the duration of surgery (MD=27.62; 95% CI, -6.26, 61.49), intraoperative complications (odd ratio [OR]=1.10; 95% CI, 0.17, 7.32), postoperative complications (OR=0.78; 95% CI, 0.33, 1.86), relapse rate (OR=1.45; 95% CI, 0.56, 3.74), and survival rate (OR=0.75; 95% CI, 0.52, 1.08) between LRH group and ARH group (all P >0.05).
Conclusions: LRH has more advantages over ARH in the treatment of cervical cancer. Still, the long-term effects and safety of LRH and ARH need more high-quality, large-sample RCTs to be further verified.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624383 | PMC |
| http://dx.doi.org/10.1097/COC.0000000000000939 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Human papillomavirus: problems and prospects for women's reproductive health (systematic review).
Pol Merkur Lekarski
September 2025
LLC "ECOFARM", KYIV, UKRAINE.
Objective: Aim: To consider the specific activity of drops and suppositories of PROTEFLAZID® at the stage of preclinical study, to assess the effectiveness and safety of use in clinical practice in papillomavirus-associated diseases of the female reproductive system..
Patients And Methods: Materials and Methods: Analysis of scientific publications on the treatment of palilomavirus infection with PROTEFLAZID® in women over the past decade.
Sociodemographic and clinical factors associated with delayed diagnosis of cervical cancer: a cross-sectional study, Brazil, 2016-2020.
Epidemiol Serv Saude
September 2025
Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil.
Objectives: To assess the time taken to diagnose cervical cancer in Brazil and identify associated sociodemographic and clinical factors in the period 2016-2020.
Methods: This was a cross-sectional study of cervical neoplasms diagnosed between 2016 and 2020, using data collected from the Hospital Cancer Registry. The logistic regression model was applied to calculate odds ratios (OR) and 95% confidence intervals (95%CI).
[Between gender and health technologies: an analysis of HPV and cervical cancer prevention campaigns from 2014 to 2020].
Cien Saude Colet
August 2025
Instituto de Medicina Social Hesio Cordeiro, Universidade do Estado do Rio de Janeiro. R. São Francisco Xavier 524, Maracanã. 20550-900 Rio de Janeiro RJ Brasil.
In this article an analysis of the preventive campaigns against cervical cancer (CC) and human papillomavirus (HPV) vaccination developed by the National Cancer Institute (INCA) of the Ministry of Health was conducted, in addition to some campaigns produced by non-governmental organizations and private institutions, from 2014 to 2020. From a socio-anthropological point of view, the objective was to understand how these health technologies trigger and produce gender representations. Seven categories of analysis were developed ("Generationality of care", "Schooling", "Childhood and Youth", "Gamification", "Health risk", "Men's health" and "Neutrality") that permitted discussion of the themes that emerged in graphic pieces.
View Article and Find Full Text PDFGaps in care across the cancer screening continuum for cervical, colorectal and lung cancer.
J Natl Cancer Inst
September 2025
Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Background: While screening for cervical, colorectal, and lung cancers reduce cancer-specific mortality, the full benefits of screening are only realized when coupled with timely care across the subsequent "screening continuum" steps, including surveillance (results warranting frequent monitoring), diagnostic evaluation (results that require additional testing), and treatment (detected cancers). Our goal was to describe the proportion of individuals receiving timely cervical, colorectal, and lung cancer care at each step in the screening continuum.
Methods: This retrospective cohort study used data from the 10 health care settings that participate in the Population-based Research to Optimize the Screening Process (PROSPR II) consortium and included individuals who were eligible for a step along the cancer screening continuum in 2018.
HPV knowledge and non-adherence to cervical cancer screening before and following the COVID-19 pandemic in the United States.
PLOS Glob Public Health
September 2025
Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, United States of America.
To compare HPV vaccination knowledge and non-adherence rates to cervical cancer screening in a nationally representative sample of American women before and following the COVID-19 pandemic, female participants aged 21-65 years from the National Cancer Institute Health Information National Trends Survey 2019 and 2022 were included. Adherence to cervical cancer screening was assessed based on the timing of their last Papanicolaou (PAP) smear, with participants classified as non-adherent to cervical cancer guidelines if their last PAP smear was > 3 years. Further, participants were asked about their knowledge of the HPV vaccine and were categorized as unaware if they had not heard of it before.
View Article and Find Full Text PDF